Showing 4841-4850 of 5623 results for "".
- Bausch + Lomb Receives FDA Clearance for Infuse Daily Disposable Silicone Hydrogel Contact Lenseshttps://modernod.com/news/bausch-lombs-infuse-daily-disposable-silicone-hydrogel-contact-lenses-receive-fda-510k-clearance-for/2477862/Bausch + Lomb has received 510(k) clearance from the FDA for the Bausch + Lomb Infuse daily disposable silicone hydrogel (SiHy daily) contact lenses. Bausch + Lomb Infuse contact lenses feature a next generation contact lens material (kalifilcon A), which is designed to meet the unmet need
- SightGlass Vision Granted CE Mark for Eyeglasses That Slow Myopia Progression in Childrenhttps://modernod.com/news/sightglass-vision-granted-ce-mark-for-novel-eyeglasses-that-slow-myopia-progression-in-children/2477859/SightGlass Vision announced it has achieved CE Mark approval for its first product – novel eyeglasses designed to slow the progression of myopia in children. The approval allows the SightGlass Vision to commercialize its suite of Diffusion Optics Technology (DOT) products across the EU,
- Re-vana Therapeutics Raises $3.25 Million in Pre-Series A Financinghttps://modernod.com/news/re-vana-therapeutics-raises-3-25-million-in-pre-series-a-financing/2477857/Re-Vana Therapeutics, a privately-held specialty therapeutic and drug delivery company developing sustained-release therapeutics for significant sight-threatening ocular diseases, announced that it has closed $3.25 mi
- Lilly Begins World’s First Human Study of Antibody to Treat COVID-19https://modernod.com/news/lilly-begins-worlds-first-human-study-of-antibody-to-treat-covid-19/2477853/Eli Lilly said that the first patients have been dosed in a phase 1 trial investigating the experimental antibody LY-CoV555 for the treatment of COVID-19. The company, which is developing the drug with partner AbCellera, noted that the move marks the world’s first study of a potential antib
- Ocugen to Discontinue Phase 3 oGVHD Trialhttps://modernod.com/news/ocugen-to-discontinue-phase-3-ogvhd-trial/2477849/Ocugen announced the decision to discontinue the phase 3 trial of OCU300 for ocular Graft vs. Host Disease (oGVHD). The decision to stop the trial is based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring committee, which indicated
- Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With GAhttps://modernod.com/news/lineage-cell-therapeutics-reports-regeneration-of-retinal-tissue-in-patient-treated-with-opregen-rpe-cells-for-dry-amd-with-ga/2477845/Lineage Cell Therapeutics announced that restoration of retinal tissue was observed in a patient enrolled in a phase 1/2a study of its lead product candidate, OpRegen, a retinal pigment epithelium (RPE) cell transplant therapy in development for the treatment of dry age-related macular degenerati
- The World Is Still Far From Herd Immunity for Coronavirushttps://modernod.com/news/the-world-is-still-far-from-herd-immunity-for-coronavirus/2477837/The coronavirus still has a long way to go. That’s the message from a crop of new studies across the world that are trying to quantify how many people have been infected, according to a New York Times
- Mynosys Changes Name to Centricity Vision; Names New Leadership Teamhttps://modernod.com/news/mynosys-changes-name-to-centricity-vision-names-new-leadership-team/2477834/Centricity Vision, formerly known as Mynosys Cellular Devices, announced a new executive leadership team, along with a new company name. Centricity Vision reflects the company’s core competency, embodied by its Zepto Precision Cataract Surgery Platform, in creating precise, consistent, vis
- Gene Therapy Program at Penn Medicine Joins AAVCOVID Vaccine Projecthttps://modernod.com/news/gene-therapy-program-at-penn-medicine-joins-aavcovid-vaccine-project/2477832/The Gene Therapy Program at the University of Pennsylvania is joining the AAVCOVID vaccine program led by Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham for the joint research program. AAVCOVID is a unique gene-based vaccine candidate designed
- A New Law in Laser Physics Could Make Eye Surgery Simplerhttps://modernod.com/news/a-new-law-in-laser-physics-could-make-eye-surgery-simpler/2477830/Scientists have developed a new type of laser that can deliver high amounts of energy in very short bursts of time, with potential applications in eye and heart surgery or the engineering of delicate materials, according to a